» Articles » PMID: 28183260

Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer

Overview
Journal Curr Med Chem
Specialty Chemistry
Date 2017 Feb 11
PMID 28183260
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The incidence of pancreatic cancer (PC) is rising in parallel with the deaths caused by this malignant disease largely due to limited improvement in current treatment strategies. In spite of aggressive PC research, for the past three decades, there has been no significant improvement in the five-year survival for this cancer. Like many other cancers, it takes several years for normal pancreatic cells to transform into pancreatic precursor lesions and to further progress into invasive carcinoma. Hence there is a scope for the development of chemo-preventive strategies to inhibit/ delay/prevent progression of this disease into an advanced stage cancer.

Objective: Chemoprevention of pancreatic cancer.

Method: Review of published literature.

Results And Conclusion: Availability of various genetically engineered mouse (GEM) models of PC has led to accelerated progress in understanding the disease and developing intervention strategies otherwise stalled for a long time. These GEM models spontaneously develop PC in a stepwise manner and mimic the disease etiology in humans. Understanding PC development from initiation to progression to metastasis is very important for early detection and prevention of PC. In this review, we focus on the current situation, the potential challenges, the progress in existing strategies and available opportunities as well as suggest key areas for research within the increasingly important area of pancreatic cancer chemoprevention.

Citing Articles

Tephrosin induces apoptosis of human pancreatic cancer cells through the generation of reactive oxygen species.

Du J, Jiang F, Xu S, Huang Z, Chen L, Li L J Cancer. 2021; 12(1):270-280.

PMID: 33391424 PMC: 7738831. DOI: 10.7150/jca.50360.


DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice.

Zheng Y, Zhang M, Li Y, Liu X, Zhen Y Cancer Biol Ther. 2020; 21(8):749-757.

PMID: 32644888 PMC: 7515518. DOI: 10.1080/15384047.2020.1776580.


Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.

Mohammed A, Janakiram N, Suen C, Stratton N, Lightfoot S, Singh A Mol Carcinog. 2019; 58(10):1908-1918.

PMID: 31313401 PMC: 6721979. DOI: 10.1002/mc.23084.


Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.

Tu M, Ho P, Zhang Q, Jian C, Qiu J, Kim E Cancer Lett. 2018; 442:82-90.

PMID: 30389433 PMC: 6311422. DOI: 10.1016/j.canlet.2018.10.038.


Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage .

Rao C, Pal S, Mohammed A, Farooqui M, Doescher M, Asch A Oncotarget. 2017; 8(34):57605-57621.

PMID: 28915699 PMC: 5593671. DOI: 10.18632/oncotarget.17745.